Ziftomenib is a small molecule commercialized by Kura Oncology, with a leading Phase II program in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to Globaldata, it is involved in 5 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ziftomenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ziftomenib is expected to reach an annual total of $57 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ziftomenib Overview
Ziftomenib (KO-539) is under development for the treatment of MLL- rearranged leukemias including NPM1 mutant or DNMT3A mutant refractory/relapsed acute myelocytic leukemia and adult and pediatric acute lymphocytic leukemia (ALL, acute lymphoblastic leukemia). The drug candidate is administered orally as a capsule. It targets menin-MLL protein interaction.
Kura Oncology Overview
Kura Oncology is a biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candidate intended for the treatment of various types of cancer including HRAS mutant head and neck cancer, peripheral T-cell lymphomas, myelodysplastic syndromes and chronic myelomonocytic leukemia. Its other candidates include KO-947, an investigational drug candidate for mitogen-activated protein kinase pathway tumors and KO-539, a small molecule inhibitor to treat acute leukemia. Kura Oncology is headquartered in San Diego, California, the US.
The operating loss of the company was US$139.9 million in FY2022, compared to an operating loss of US$131.5 million in FY2021. The net loss of the company was US$135.8 million in FY2022, compared to a net loss of US$130.5 million in FY2021.
For a complete picture of Ziftomenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.